Julphar net income from operations jumps to AED 89 million
Julphar reported nine-month revenue of AED 906.0 million, up 13.5% year-on-year.
· Last verified: 14 Nov 2026 (Julphar (Gulf Pharmaceutical Industries PSC), Al Bayan)

Summary
- Julphar reported nine-month revenue of AED 906.0 million, up 13.5% year-on-year.
- Net income from continuing operations reached AED 89.0 million, against AED 8.1 million a year earlier.
- Accumulated losses fell to AED 74.0 million, easing pressure on the drugmaker's balance sheet.
The latest
Net income from continuing operations at Ras Al Khaimah drugmaker Julphar reached AED 89.0 million in the first nine months of 2026, more than ten times the AED 8.1 million booked a year earlier, the Abu Dhabi-listed company said. Revenue rose 13.5% to AED 906.0 million. The company attributed the improvement to better product mix, operational efficiency and lower financing costs.
Details
- The headline numbers: Gulf Pharmaceutical Industries (Julphar) said revenue from continuing operations hit AED 906.0 million for the nine months ended 30 September 2026, against AED 797.9 million a year earlier. Gross profit rose 23.5% to AED 394.3 million, and EBITDA from continuing operations climbed 90.3% to AED 126.0 million from AED 66.2 million.
- The underlying rate: The company said reported growth included quarter-to-quarter sales phasing after geopolitical disruption, plus certain non-recurring sales transactions. Stripping those out, Julphar put underlying revenue growth at 6.4% — less than half the headline 13.5% figure it led with.
- Where growth came from: Other international markets were the strongest contributor, with revenue up 28.6% to AED 335.0 million, according to the statement. UAE revenue rose 9.0% to AED 340.7 million, while other GCC markets grew just 2.4% to AED 230.3 million.
- The total-profit gap: Total net income for the period was AED 87.5 million, down from AED 138.2 million in the same months of 2025. Julphar said the prior-year figure included a one-off net capital gain of AED 118.7 million from the divestment of Zahrat Al Rawdah Pharmacies LLC.
- Balance sheet: Total equity rose to AED 1,046.9 million from AED 959.8 million at end-December 2025, with accumulated losses cut to AED 74.0 million from AED 163.0 million at the start of the year. Interest-bearing debt stood at AED 263.8 million.
- Pipeline and expansion: Julphar said it launched four new products in the UAE and completed 27 international registrations during the nine months. Work continued on a new manufacturing facility in Saudi Arabia, alongside licensing activity, in-house R&D and pipeline expansion covering selected biotechnology and specialty products.
- Capital spending: Capital expenditure totalled AED 27.3 million, directed at infrastructure upgrades, equipment modernization, process optimization and research and development. Julphar did not break the spending down by project or set a completion date for the Saudi plant.
- Management framing: Chairman Sheikh Saqr Humaid Al Qasimi said the results reflect disciplined execution and a solid foundation for sustainable long-term growth. Chief Executive Basel Ziyadeh pointed to improved product mix, operational efficiency and financial discipline as the drivers of the profitability increase.
- Cost backdrop: The company said the performance came despite regional geopolitical developments, global supply-chain disruption, inflationary pressures and higher logistics and material costs, citing efficiency measures, risk management and supply-chain diversification as offsetting factors.
Background
Julphar completed a debt restructuring in 2025, after which the company says it has maintained a stable financing position. Its 2025 results were also shaped by the sale of Zahrat Al Rawdah Pharmacies, a disposal that inflated the comparative profit base now being measured against.
Between the lines
Two numbers point in opposite directions. Operating performance improved sharply — EBITDA nearly doubled and net income from continuing operations rose from AED 8.1 million to AED 89.0 million — while total net income fell, purely because last year carried a AED 118.7 million asset-sale gain that will not repeat. The 6.4% underlying revenue figure the company disclosed is the cleaner read on demand.
What's next
Full-year 2026 results will show whether the non-recurring sales that lifted nine-month revenue reverse in the fourth quarter, and whether accumulated losses, now AED 74.0 million, are cleared. A construction timeline for the Saudi plant remains unannounced.
Source: Julphar (Gulf Pharmaceutical Industries PSC), Al Bayan